Janus Henderson Group
DYN icon

Janus Henderson Group’s Dyne Therapeutics DYN Stock Holding History

Janus Henderson Group’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$247M Sell
13,647,376
-240,346
-2% -$4.14M 0.12% 170
2025
Q4 		$272M Sell
13,887,722
-857,783
-6% -$16.2M 0.12% 162
2025
Q3 		$186M Buy
14,745,505
+5,307,543
+56% +$60.5M 0.09% 193
2025
Q2 		$89.9M Sell
9,437,962
-915,454
-9% -$10.1M 0.04% 281
2025
Q1 		$118M Buy
10,353,416
+2,974,107
+40% +$42.5M 0.06% 242
2024
Q4 		$174M Buy
7,379,309
+566,146
+8% +$16.7M 0.09% 207
2024
Q3 		$245M Buy
6,813,163
+2,189,339
+47% +$87.1M 0.13% 169
2024
Q2 		$163M Buy
4,623,824
+1,948,584
+73% +$56.6M 0.09% 197
2024
Q1 		$75.9M Buy
2,675,240
+2,663,910
+23,512% +$60.2M 0.04% 310
2023
Q4 		$151K Sell
11,330
-34
-0.3% -$332 ﹤0.01% 2486
2023
Q3 		$102K Buy
11,364
+14
+0.1% +$151 ﹤0.01% 2515
2023
Q2 		$128K Buy
11,350
+11
+0.1% +$130 ﹤0.01% 2544
2023
Q1 		$130K Buy
+11,339
New +$147K ﹤0.01% 2582
2022
Q4 		– Sell
-1,531,906
Closed -$19.5M – 2469
2022
Q3 		$19.5M Buy
1,531,906
+471,605
+44% +$5.41M 0.01% 681
2022
Q2 		$7.29M Sell
1,060,301
-122,405
-10% -$843K 0.01% 765
2022
Q1 		$11.4M Buy
1,182,706
+600,408
+103% +$5.11M 0.01% 864
2021
Q4 		$6.92M Buy
582,298
+23,815
+4% +$335K ﹤0.01% 989
2021
Q3 		$9.07M Sell
558,483
-8,683
-2% -$154K ﹤0.01% 928
2021
Q2 		$11.9M Sell
567,166
-296,908
-34% -$5.58M 0.01% 906
2021
Q1 		$13.4M Buy
864,074
+234,222
+37% +$4.53M 0.01% 850
2020
Q4 		$13.2M Sell
629,852
-356,111
-36% -$7.04M 0.01% 830
2020
Q3 		$19.9M Buy
+985,963
New +$21.6M 0.01% 710

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Janus Henderson Group's DYN Position: Q1 2026 in Review

Janus Henderson Group reduced its Dyne Therapeutics (DYN) stake by 1.7% in Q1 2026, selling an estimated $4.14M and leaving 13,647,376 shares worth $247M. The position accounts for 0.12% of the portfolio, ranked #170.

Janus Henderson Group first reported a position in DYN in Q3 2020 and has held it in 22 quarters since. The position peaked at $272M in Q4 2025. 227 funds tracked by Wall St. Rank hold DYN as of Q1 2026.

  • Janus Henderson Group held 13,647,376 shares of Dyne Therapeutics worth $247M as of Q1 2026.
  • Janus Henderson Group sold 240,346 Dyne Therapeutics shares in Q1 2026, an estimated $4.14M.
  • Dyne Therapeutics made up 0.12% of Janus Henderson Group's portfolio in Q1 2026, its #170 holding.
  • Janus Henderson Group first reported a position in Dyne Therapeutics in Q3 2020 and has held it in 22 quarters since.
  • Janus Henderson Group's Dyne Therapeutics position peaked at $272M in Q4 2025.
  • 227 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q1 2026.

Based on Janus Henderson Group's 13F filing for Q1 2026, filed 15 May 2026.